Last reviewed · How we verify
MultiHance 0.1 mmol/kg
MultiHance 0.1 mmol/kg is a Paramagnetic contrast agent; gadolinium-based MRI contrast medium Small molecule drug developed by Bracco Diagnostics, Inc. It is currently FDA-approved for MRI of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues, Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease, Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease.
MultiHance (gadobenate dimeglumine) 0.1 mmol/kg is a marketed paramagnetic contrast agent developed by Bracco Diagnostics for MRI and MRA applications. The drug enhances visualization of CNS lesions with abnormal blood-brain barrier or vascularity in adults and pediatric patients, and evaluates renal and aorto-ilio-femoral vascular disease in adults. With 21 clinical trials and 160 publications supporting its use, MultiHance demonstrates robust clinical validation in diagnostic imaging. The agent's mechanism leverages paramagnetic properties to shorten T1 and T2 relaxation times, producing enhanced signal intensity in MRI sequences. As an established contrast agent with broad clinical applications across CNS and vascular imaging, MultiHance represents a significant diagnostic tool in the contrast media market with sustained commercial relevance.
At a glance
| Generic name | MultiHance 0.1 mmol/kg |
|---|---|
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Paramagnetic contrast agent; gadolinium-based MRI contrast medium |
| Target | Water protons in tissue; blood-brain barrier; vascular endothelium |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- MRI of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues
- Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease
- Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease
Boxed warnings
- WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use [see Warnings and Precautions (5.1) ] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination o
Common side effects
Drug interactions
- cisplatin
- doxorubicin
- daunorubicin
- vincristine
- methotrexate
- etoposide
- tamoxifen
- paclitaxel
Key clinical trials
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PHASE2)
- Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions (PHASE3)
- 3-Tesla MRI Response to TACE in HCC (Liver Cancer) (NA)
- Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI (NA)
- Crossover Comparison of MultiHance and Dotarem (PHASE4)
- Contrast-enhanced MRI in Children 2 Months to <2 Years (PHASE3)
- Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients (PHASE3)
- Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MultiHance 0.1 mmol/kg CI brief — competitive landscape report
- MultiHance 0.1 mmol/kg updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI
Frequently asked questions about MultiHance 0.1 mmol/kg
What is MultiHance 0.1 mmol/kg?
What is MultiHance 0.1 mmol/kg used for?
Who makes MultiHance 0.1 mmol/kg?
What drug class is MultiHance 0.1 mmol/kg in?
What development phase is MultiHance 0.1 mmol/kg in?
What does MultiHance 0.1 mmol/kg target?
Related
- Drug class: All Paramagnetic contrast agent; gadolinium-based MRI contrast medium drugs
- Target: All drugs targeting Water protons in tissue; blood-brain barrier; vascular endothelium
- Manufacturer: Bracco Diagnostics, Inc — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for MRI of the central nervous system (CNS) in adults and pediatric patients (including term neonates) to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues
- Indication: Drugs for Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease
- Indication: Drugs for Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected aorto-ilio-femoral occlusive vascular disease
- Compare: MultiHance 0.1 mmol/kg vs similar drugs
- Pricing: MultiHance 0.1 mmol/kg cost, discount & access